An immune response can broaden to recognize additional epitopes over time. Showing that broadening requires measurements of the added specificities.
A follow-up study of a small melanoma neoantigen-vaccine cohort found persistent immune responses, evolving receptor clonotypes and evidence of responses beyond the original vaccine targets. The report provides clinical immune-monitoring evidence of spreading in that cohort. The response measurements are distinct from a randomized estimate of treatment benefit. Spreading should not be inferred solely from an increased total lymphocyte count or expansion of an unidentified receptor sequence.
Shares Immunodominance, T-cell receptor repertoire sequencing, Immune measurements and product evidence.
Shares Immunodominance, Immune measurements and product evidence.
Shares Immunogenicity and clinical efficacy, Immune measurements and product evidence.
Shares T-cell receptor repertoire sequencing, Immune measurements and product evidence.
Shares T-cell receptor repertoire sequencing, Immune measurements and product evidence.
Shares Immunogenicity and clinical efficacy, Immune measurements and product evidence.
Shares Immunogenicity and clinical efficacy, Immune measurements and product evidence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/